We are currently initiating a trial with inebilizumab in ME/CFS and PCS patients, a monoclonal antibody directed against CD19 on B cells and plasma blasts showing high clinical efficacy in neuromyelitis optica.43 This evidence concerns the gene CD19 and neuromyelitis optica.